These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21516942)

  • 1. Proceedings of the 2009 Viral Clearance Symposium.
    Miesegaes G; Bailey M; Willkommen H; Chen Q; Roush D; Blümel J; Brorson K
    Dev Biol (Basel); 2010; 133():3-101. PubMed ID: 21516942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proceedings of the 2017 Viral Clearance Symposium, Session 6: Ensuring Viral Safety in Continuous Processing.
    Johnson SA; Roush D
    PDA J Pharm Sci Technol; 2018; 72(5):516-524. PubMed ID: 30030352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proceedings of the 2017 Viral Clearance Symposium, Session 2.2: DSP Unit Operations-Purification Unit Operations.
    Roush D; Kreil TR
    PDA J Pharm Sci Technol; 2018; 72(5):479-487. PubMed ID: 30030354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proceedings of the 2017 Viral Clearance Symposium, Session 2.1: DSP Unit Operations-Virus Filtration/Inactivation.
    Kreil TR; Roush D
    PDA J Pharm Sci Technol; 2018; 72(5):470-478. PubMed ID: 30030356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
    Ma J; Kreil TR
    PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proceedings of the 2017 Viral Clearance Symposium.
    Hepbildikler S; Nothelfer F
    PDA J Pharm Sci Technol; 2018; 72(5):453-454. PubMed ID: 30030350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
    Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
    PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of viral clearance unit operations for monoclonal antibodies.
    Miesegaes G; Lute S; Brorson K
    Biotechnol Bioeng; 2010 Jun; 106(2):238-46. PubMed ID: 20073086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceedings of the 2019 Viral Clearance Symposium, Session 1: Viral Clearance Strategies and Case Studies.
    Reitz S; Schwantes A
    PDA J Pharm Sci Technol; 2022; 76(4):297-305. PubMed ID: 34911829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proceedings of the 2019 Viral Clearance Symposium: Introduction.
    O'Donnell S
    PDA J Pharm Sci Technol; 2022; 76(4):295-296. PubMed ID: 34911827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Evaluation of Cycled Resin in Viral Clearance Studies-A Multiple Company Collaboration.
    Mattila J; Curtis S; Webb-Vargas Y; Wilson E; Galperina O; Roush D; Tobler S; Stanley B; Clark M; Weaver J; Pike J; Yu D; Li X; Flicker A; Kindermann J; Schuelke N; Whitcombe R; Bennett L
    PDA J Pharm Sci Technol; 2019; 73(5):470-486. PubMed ID: 31101706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proceedings of the 2019 Viral Clearance Symposium, Session 8. Conference Summary: Key Discussion and Outcomes, Pending Questions, and Proposed Experiments and Actions.
    Bolton G
    PDA J Pharm Sci Technol; 2022; 76(4):362-367. PubMed ID: 34911826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meeting Report: 2013 PDA Virus & TSE Safety Forum.
    Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Hubbard BR; Kreil TR; Ruffing M; Ruiz S; Scott D; Silvester G
    PDA J Pharm Sci Technol; 2014; 68(3):193-214. PubMed ID: 25188343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proceedings of the 2019 Viral Clearance Symposium, Session 2: New Modalities in Chromatography and Adsorptive Filters.
    Specht R; Schwantes A
    PDA J Pharm Sci Technol; 2022; 76(4):306-314. PubMed ID: 34911828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Evaluation of Low-pH Viral Inactivation and Viral Filtration Data from a Multiple Company Collaboration.
    Mattila J; Clark M; Liu S; Pieracci J; Gervais TR; Wilson E; Galperina O; Li X; Roush D; Zoeller K; Brough H; Simpson-Platre C
    PDA J Pharm Sci Technol; 2016; 70(3):293-9. PubMed ID: 27020645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proceedings of the 2017 Viral Clearance Symposium, Session 1.2: Upstream Mitigation, Part 2-Virus Barrier Filter and HTST.
    Chen D; Bolton G
    PDA J Pharm Sci Technol; 2018; 72(5):462-469. PubMed ID: 30030355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proceedings of the 2019 Viral Clearance Symposium, Session 5: Viral Inactivation.
    Ma J
    PDA J Pharm Sci Technol; 2022; 76(4):339-348. PubMed ID: 34911831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proceedings of the 2017 Viral Clearance Symposium: Conclusion.
    Hepbildikler S; Johnson S; Bluemel J
    PDA J Pharm Sci Technol; 2018; 72(5):525-530. PubMed ID: 30030353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
    Roberts PL; Dunkerley C; Walker C
    Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral clearance using disposable systems in monoclonal antibody commercial downstream processing.
    Zhou JX; Solamo F; Hong T; Shearer M; Tressel T
    Biotechnol Bioeng; 2008 Jun; 100(3):488-96. PubMed ID: 18438883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.